Cellectis S.A. (NASDAQ:CLLS) Short Interest Down 9.2% in July

Cellectis S.A. (NASDAQ:CLLSGet Rating) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 887,300 shares, a drop of 9.2% from the July 15th total of 976,800 shares. Based on an average daily trading volume, of 144,700 shares, the short-interest ratio is presently 6.1 days. Approximately 2.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several analysts have weighed in on CLLS shares. The Goldman Sachs Group lowered their target price on shares of Cellectis from $3.00 to $2.00 and set a “sell” rating for the company in a research note on Tuesday, May 24th. Barclays lowered their price objective on shares of Cellectis from $9.00 to $7.00 in a research note on Friday, May 13th. StockNews.com raised shares of Cellectis from a “sell” rating to a “hold” rating in a report on Friday, August 5th. Finally, Robert W. Baird raised shares of Cellectis from a “neutral” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research note on Wednesday, May 18th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Cellectis currently has a consensus rating of “Hold” and an average price target of $14.17.

Institutional Trading of Cellectis

Institutional investors have recently bought and sold shares of the company. State Street Corp raised its stake in shares of Cellectis by 112.2% during the 2nd quarter. State Street Corp now owns 253,725 shares of the biotechnology company’s stock worth $718,000 after purchasing an additional 134,164 shares in the last quarter. Millennium Management LLC increased its stake in shares of Cellectis by 12.4% during the 2nd quarter. Millennium Management LLC now owns 452,941 shares of the biotechnology company’s stock worth $1,282,000 after purchasing an additional 50,039 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Cellectis during the 2nd quarter worth $46,000. Principal Financial Group Inc. raised its holdings in shares of Cellectis by 11.0% during the 2nd quarter. Principal Financial Group Inc. now owns 1,348,312 shares of the biotechnology company’s stock valued at $3,816,000 after purchasing an additional 133,587 shares in the last quarter. Finally, Capital Wealth Alliance LLC acquired a new stake in shares of Cellectis in the 2nd quarter valued at $680,000. Institutional investors and hedge funds own 40.55% of the company’s stock.

Cellectis Stock Down 6.5 %

Cellectis stock traded down $0.26 during trading hours on Wednesday, hitting $3.72. The company had a trading volume of 2,195 shares, compared to its average volume of 144,040. Cellectis has a fifty-two week low of $2.30 and a fifty-two week high of $15.50. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.17 and a quick ratio of 3.17. The firm has a market capitalization of $169.30 million, a P/E ratio of -1.52 and a beta of 2.11. The firm’s fifty day moving average is $2.93 and its 200-day moving average is $3.78.

Cellectis Company Profile

(Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

See Also

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.